Log In
BCIQ
Print this Print this
 

ARCHITECT Anti-CCP assay

  Manage Alerts
Collapse Summary General Information
Company Alere Inc.
DescriptionAnti-cyclic citrullinated peptide assay for the ARCHITECT i system
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationAutoimmune, Diagnostic
Indication DetailsDetect rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$8,400.0M

$5,800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/01/2016

$8,400.0M

$5,800.0M

0

Get a free BioCentury trial today